Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?

Johnson & Johnson (JNJ -0.47%) has a diverse healthcare business, and investors often look to it as a safe dividend stock to invest in for the long term. One area where it has been lacking, however, is growth. The company's growth is often in the single digits and with top-selling drug Stelara losing patent protection and its sales already declining, investors are concerned about J&J's long-term growth prospects. As a result, the stock has been a largely underwhelming buy of late, with its shares down 5% ov ...